Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL

Kidney International

Volumn 65, Issue 6, 2004, Pages 2309-2320

  De Zeeuw, Dick ^a   Remuzzi, Giuseppe ^b   Parving, Hans Henrik ^b   Keane, William F ^b   Zhang, Zhongxin ^b   Shahinfar, Shahnaz ^b   Snapinn, Steve ^b   Cooper, Mark E ^b   Mitch, William E ^b   Brenner, Barry M ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b NONE

Author keywords

Albuminuria progressive renal function loss; Angiotensin II antagonism; Proteinuria; Type 2 diabetes

Indexed keywords

ANGIOTENSIN II ANTAGONIST; CHOLESTEROL; CREATININE; HEMOGLOBIN; HEMOGLOBIN A1C; LOSARTAN; PLACEBO;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BIOLOGICAL MONITORING; BLOOD PRESSURE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEATH; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DISEASE MARKER; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EVALUATION; FEMALE; FOLLOW UP; GENDER; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; PROTECTION; PROTEINURIA; RACE; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; SITTING; SMOKING; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

EID: 2442680120     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.00653.x     Document Type: Article

References (34)

1. AMOS A, MCCARTY D, ZIMMET P: The rising global burden of diabetes and its complications: Estimates and projections to the year 2010. Diabetes Med 14(Suppl 5):S1-S85, 1997
2. KING H, AUBERT R, HERMAN W: Global burden of diabetes 1995-2025. Prevalence, numerical estimates and projections. Diabetes Care 21:1414-1431, 1998
3. PARVING H-H: Diabetic nephropathy: Prevention and treatment. Kidney Int 60:2041-2055, 2001
4. REMUZZI G, SCHIEPPATI A, RUGGENENTI P: Nephropathy in patients with type 2 diabetes. N Engl J Med 346:1145-1151, 2002
5. AMERICAN DIABETES ASSOCIATION: Management of dyslipidemia in adults with diabetes. Diabetes Care 26(Suppl 1):S83-S86, 2003
6. REMUZZI G, RUGGENENTI P, PERICO N: Chronic renal diseases: renal protective benefits of renin-angiotensin system inhibition. Ann Intern Med 136:604-615, 2002
7. KEANE WF, BRENNER BM, DE ZEEUW D, et al: The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL Study. Kidney Int 63:1499-1507, 2003
8. JAFAR TH, SCHMID CH, LANDA M, et al: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 135(2):73-87, 2001
9. LEWIS EJ, HUNSICKER LG, BAIN RP, ROHDE RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462, 1993
10. LEWIS EJ, HUNSICKER LG, CLARKE WR, et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
11. BRENNER BM, COOPER MA, DE ZEEUW D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
12. De JONG PE, NAVIS G, DE ZEEUW D: Renoprotective therapy: Titration against urinary protein excretion. Lancet 354:352-353, 1999
13. BRENNER BM, COOPER ME, DE ZEEUW D, et al: The losartan renal protection study - Rationale, study design and baseline characteristics of RENAAL (Reduction of End Points in NIDDM with the Angiotensin II Antagonist Losartan). J RAAS 1:328-335, 2000
14. WILLIAMS PS, FASS G, BONE JM: Renal pathology and proteinuria determine progression in untreated mild/moderate chronic renal failure. Q J Med 67:343-354, 1988
15. REMUZZI G, BERTANI T: Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int 38:384-394, 1990
16. ROSSING P, HOMMEL E, SMIDT UM, PARVING H-H: Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients. Diabetes 42:715-719, 1993
17. BREYER JA, BAIN P, EVANS JK, et al: Predictors of the progression of renal insufficiency in patients with insulin dependent diabetes and over diabetic nephropathy. Kidney Int 50:1651-1658, 1996
18. YOKOYAMA H, TOMONAGA O, HIRAYAMA M, et al: Predictors of the progression of diabetic nephropathy and the beneficial effect of ACEi in NIDDM patients. Diabetologia 40:405-411, 1997
19. PETERSON JC, ADLER S, BURKART JM, et al: Blood pressure control, proteinuria, and the progression of renal disease. MDRD. Ann Intern Med 123:754-762, 1995
20. PARVING H-H, HOVIND P, ROSSING K, ANDERSEN S: Evolving strategies for renoprotection: Diabetic nephropathy. Curr Opin Nephrol Hypertens 10:515-522, 2001
21. BIANCHI S, BIGAZZI R, CAIAZZA A, CAMPESE VM: A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 41:565-570, 2003
22. EL NAHAS AM, MASTERS-THOMAS A, BRADY SA, et al: Selective effect of low protein diets in chronic renal diseases. Br Med J (Clin Res) 289:1337-1341, 1984
23. VRIESENDORP R, DONKER AJM, DE ZEEUW D, et al: Effects of nonsteroidal anti-inflammatory drugs on proteinuria. Am J Med 81(Suppl 2B):84-94, 1986
24. KASISKE BL, KALIL R, MA JZ, et al: Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 118:129-138, 1993
25. GANSEVOORT RT, SLUITER WJ, HEMMELDER MH, et al: Antiproteinuric effect of blood-pressure-lowering agents: A meta-analysis of comparative trials. Nephrol Dial Transplant 10:1963-1974, 1995
26. GANSEVOORT RT, DE ZEEUW D, DE JONG PE: Is the antiproteinuric effect of ACE inhibition mediated by interference in the reninangiotensin system? Kidney Int 45:861-867, 1994
27. PERICO N, REMUZZI A, SANGALLI F, et al: The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin. J Am Soc Nephrol 9:2308-2317, 1998
28. MASCHIO G, ALBERTI D, JANIN G, et al: Effect of the angiotensin- converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 334:939-945, 1996
29. THE GISEN GROUP: Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349:1857-1863, 1997
30. ROSSING P, HOMMEL E, SMIDT UM, PARVING H-H: Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia 37:511-516, 1994
31. APPERLOO AJ, DE ZEEUW D, DE JONG PE: Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease. Kidney Int 45(Suppl 45):S174-S178, 1994
32. LAVERMAN GD, HENNING RH, DE JONG PE, et al: Optimal antiproteinuric dose of losartan in non-diabetic patients with nephrotic range proteinuria. Am J Kidney Dis 38:1381-1384, 2001
33. ANDERSEN S, ROSSING P, JUHL TR, et al: Optimal dose of losartan for renoprotection in diabetic nephropathy. Nephrol Dial Transplant 17:1413-1418, 2002
34. WEINBERG MS, WEINBERG AJ, CORD R, ZAPPE DH: The effect of high-dose angiotensin II receptor blockade beyond maximal recommended doses in reducing urinary protein secretion. J RAAS 2(Suppl 1):S196-S198, 2001